Treatment strategies and treatment-related adverse events in MG according to the age of onset
IntroductionEarly-onset (EOMG) and late-onset (LOMG) are distinct groups of MG patients. It is unclear if treatment strategies and treatment-related adverse events may differ according to the age of MG onset.MethodsThis single-center retrospective study includes all MG patients followed at a tertiar...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-03-01
|
| Series: | Frontiers in Neurology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2024.1277420/full |
| _version_ | 1797266426718846976 |
|---|---|
| author | João Moura João Moura Joana Fernandes Maria João Lima Ana Paula Sousa Raquel Samões Raquel Samões Raquel Samões Ana Martins Silva Ana Martins Silva Ana Martins Silva Ernestina Santos Ernestina Santos Ernestina Santos |
| author_facet | João Moura João Moura Joana Fernandes Maria João Lima Ana Paula Sousa Raquel Samões Raquel Samões Raquel Samões Ana Martins Silva Ana Martins Silva Ana Martins Silva Ernestina Santos Ernestina Santos Ernestina Santos |
| author_sort | João Moura |
| collection | DOAJ |
| description | IntroductionEarly-onset (EOMG) and late-onset (LOMG) are distinct groups of MG patients. It is unclear if treatment strategies and treatment-related adverse events may differ according to the age of MG onset.MethodsThis single-center retrospective study includes all MG patients followed at a tertiary center since 2007. We reviewed the electronic clinical records.ResultsIn total, 212 patients were identified, 142 (67.0%) females, with a median disease duration of 10 years. The median age of symptom onset was 42.0 (26.0–64.5) years, with 130 (61.3%) EOMG cases and 82 (38.7%) LOMG. EOMG were more frequently female, had longer disease duration and often more generalized MG (p < 0.001). Comorbidities were significantly more frequent in LOMG (67.1%) compared to EOMG (53.1%) (p = 0.002). Steroid-related adverse effects motivating the switch to steroid-sparing agents (82.0%) were different between groups, with hypertension, hypercholesterolemia, diabetes mellitus and malignancies being more common in LOMG. At the same time, osteoporosis and dyspepsia were more frequent in EOMG (p < 0.001). The most common first-line choice was azathioprine (45.8%), and rituximab was used in 4 patients (1.9%).ConclusionOur study shows that treatment modalities are similar between EOMG and LOMG, while steroid-related adverse events appear to be distinct. |
| first_indexed | 2024-04-25T01:00:30Z |
| format | Article |
| id | doaj.art-65bd4661da4c44ffaaaa54d80b86bc52 |
| institution | Directory Open Access Journal |
| issn | 1664-2295 |
| language | English |
| last_indexed | 2024-04-25T01:00:30Z |
| publishDate | 2024-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neurology |
| spelling | doaj.art-65bd4661da4c44ffaaaa54d80b86bc522024-03-11T05:04:46ZengFrontiers Media S.A.Frontiers in Neurology1664-22952024-03-011510.3389/fneur.2024.12774201277420Treatment strategies and treatment-related adverse events in MG according to the age of onsetJoão Moura0João Moura1Joana Fernandes2Maria João Lima3Ana Paula Sousa4Raquel Samões5Raquel Samões6Raquel Samões7Ana Martins Silva8Ana Martins Silva9Ana Martins Silva10Ernestina Santos11Ernestina Santos12Ernestina Santos13Department of Neurology, Centro Hospitalar Universitário de Santo António, Porto, PortugalUnit of Multidisciplinary Research in Biomedicine (UMIB), Instituto de Ciências Biomédicas Abel Salazar (ICBAS), University of Porto, Porto, PortugalDepartment of Neurology, Centro Hospitalar Universitário de Santo António, Porto, PortugalDepartment of Neurology, Unidade Local de Saúde de Matosinhos, Porto, PortugalDepartment of Neurophysiology, Hospital de Santo António, Centro Hospitalar Universitário Do Porto, Porto, PortugalDepartment of Neurology, Centro Hospitalar Universitário de Santo António, Porto, PortugalUnit of Multidisciplinary Research in Biomedicine (UMIB), Instituto de Ciências Biomédicas Abel Salazar (ICBAS), University of Porto, Porto, PortugalLaboratory for Integrative and Translational Research in Population Health (ITR), Porto, PortugalDepartment of Neurology, Centro Hospitalar Universitário de Santo António, Porto, PortugalUnit of Multidisciplinary Research in Biomedicine (UMIB), Instituto de Ciências Biomédicas Abel Salazar (ICBAS), University of Porto, Porto, PortugalLaboratory for Integrative and Translational Research in Population Health (ITR), Porto, PortugalDepartment of Neurology, Centro Hospitalar Universitário de Santo António, Porto, PortugalUnit of Multidisciplinary Research in Biomedicine (UMIB), Instituto de Ciências Biomédicas Abel Salazar (ICBAS), University of Porto, Porto, PortugalLaboratory for Integrative and Translational Research in Population Health (ITR), Porto, PortugalIntroductionEarly-onset (EOMG) and late-onset (LOMG) are distinct groups of MG patients. It is unclear if treatment strategies and treatment-related adverse events may differ according to the age of MG onset.MethodsThis single-center retrospective study includes all MG patients followed at a tertiary center since 2007. We reviewed the electronic clinical records.ResultsIn total, 212 patients were identified, 142 (67.0%) females, with a median disease duration of 10 years. The median age of symptom onset was 42.0 (26.0–64.5) years, with 130 (61.3%) EOMG cases and 82 (38.7%) LOMG. EOMG were more frequently female, had longer disease duration and often more generalized MG (p < 0.001). Comorbidities were significantly more frequent in LOMG (67.1%) compared to EOMG (53.1%) (p = 0.002). Steroid-related adverse effects motivating the switch to steroid-sparing agents (82.0%) were different between groups, with hypertension, hypercholesterolemia, diabetes mellitus and malignancies being more common in LOMG. At the same time, osteoporosis and dyspepsia were more frequent in EOMG (p < 0.001). The most common first-line choice was azathioprine (45.8%), and rituximab was used in 4 patients (1.9%).ConclusionOur study shows that treatment modalities are similar between EOMG and LOMG, while steroid-related adverse events appear to be distinct.https://www.frontiersin.org/articles/10.3389/fneur.2024.1277420/fullmyasthenia gravislate-onsetcomorbiditiessteroid-sparingimmunosuppression |
| spellingShingle | João Moura João Moura Joana Fernandes Maria João Lima Ana Paula Sousa Raquel Samões Raquel Samões Raquel Samões Ana Martins Silva Ana Martins Silva Ana Martins Silva Ernestina Santos Ernestina Santos Ernestina Santos Treatment strategies and treatment-related adverse events in MG according to the age of onset Frontiers in Neurology myasthenia gravis late-onset comorbidities steroid-sparing immunosuppression |
| title | Treatment strategies and treatment-related adverse events in MG according to the age of onset |
| title_full | Treatment strategies and treatment-related adverse events in MG according to the age of onset |
| title_fullStr | Treatment strategies and treatment-related adverse events in MG according to the age of onset |
| title_full_unstemmed | Treatment strategies and treatment-related adverse events in MG according to the age of onset |
| title_short | Treatment strategies and treatment-related adverse events in MG according to the age of onset |
| title_sort | treatment strategies and treatment related adverse events in mg according to the age of onset |
| topic | myasthenia gravis late-onset comorbidities steroid-sparing immunosuppression |
| url | https://www.frontiersin.org/articles/10.3389/fneur.2024.1277420/full |
| work_keys_str_mv | AT joaomoura treatmentstrategiesandtreatmentrelatedadverseeventsinmgaccordingtotheageofonset AT joaomoura treatmentstrategiesandtreatmentrelatedadverseeventsinmgaccordingtotheageofonset AT joanafernandes treatmentstrategiesandtreatmentrelatedadverseeventsinmgaccordingtotheageofonset AT mariajoaolima treatmentstrategiesandtreatmentrelatedadverseeventsinmgaccordingtotheageofonset AT anapaulasousa treatmentstrategiesandtreatmentrelatedadverseeventsinmgaccordingtotheageofonset AT raquelsamoes treatmentstrategiesandtreatmentrelatedadverseeventsinmgaccordingtotheageofonset AT raquelsamoes treatmentstrategiesandtreatmentrelatedadverseeventsinmgaccordingtotheageofonset AT raquelsamoes treatmentstrategiesandtreatmentrelatedadverseeventsinmgaccordingtotheageofonset AT anamartinssilva treatmentstrategiesandtreatmentrelatedadverseeventsinmgaccordingtotheageofonset AT anamartinssilva treatmentstrategiesandtreatmentrelatedadverseeventsinmgaccordingtotheageofonset AT anamartinssilva treatmentstrategiesandtreatmentrelatedadverseeventsinmgaccordingtotheageofonset AT ernestinasantos treatmentstrategiesandtreatmentrelatedadverseeventsinmgaccordingtotheageofonset AT ernestinasantos treatmentstrategiesandtreatmentrelatedadverseeventsinmgaccordingtotheageofonset AT ernestinasantos treatmentstrategiesandtreatmentrelatedadverseeventsinmgaccordingtotheageofonset |